Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-RTS-hIL-12 + veledimex
- Development stage
- Unknown
- Lead developer
- Alaunos Therapeutics
- Modality
- Small Molecules, Gene Therapies
- Administration
- Intratumoral, Oral
01
Overview
Ad-RTS-hIL-12 + veledimex is a novel gene therapy combination where Ad-RTS-hIL-12 is an inducible adenoviral vector engineered to express human interleukin-12 (IL-12) under the control of the RheoSwitch Therapeutic System® gene switch. Veledimex is an oral activator ligand that controls the expression of IL-12. When administered, veledimex crosses the blood-brain barrier and activates the gene switch, allowing for controlled production of IL-12, which enhances the immune system's ability to kill tumor cells by promoting activation of natural killer cells, inducing secretion of interferon-gamma, and potentially interfering with blood flow to tumors. This controlled immunogene therapy approach extends the IL-12 therapeutic window while managing toxicity.
- Brand names
- RheoSwitch Therapeutic System
- Other names
- Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on Ad-RTS-hIL-12 + veledimex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-RTS-hIL-12 + veledimex.